Artificial Intelligence in Central Nervous System Autoimmune Diseases
A systematic review highlights the use of artificial intelligence (AI) for data integration in neuroimmunology, noting that multiple sclerosis (MS) has the most extensive published research, particularly in neuroimaging. The review emphasizes that AI applications generate associations and hypotheses rather than demonstrating validated therapeutic benefits.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
Understanding AI's potential in managing autoimmune diseases like MS could offer insights into future diagnostic and treatment strategies, especially in areas where clinical phenotypes overlap and biomarkers are imperfect.
What this does not prove
The review does not establish clinical benefits and notes that research in related conditions like NMOSD, AE, and MOGAD is limited by smaller, heterogeneous studies without external validation.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not applicable
- Relevant MS type
- Not reported
- Publication date
- 2026-10-13
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceArtificial intelligence in central nervous system autoimmune diseases: from clinical decision support to mechanistic discovery and translation. ↗DOI: 10.1038/s44321-026-00527-0
Supporting passages (6)
study phaseCentral nervous system (CNS) autoimmune diseases, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), autoimmune encephalitis (AE), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), remain difficult to diagnose, stratify, and treat because clinical phenotypes overlap, biomarkers are imperfect, and the disease course requires longitudinal observation.
study designThis Review maps reported applications, evidence patterns, and methodological and implementation needs rather than ranking translational maturity or implying established clinical benefit.
primary endpoint metThis Review maps reported applications, evidence patterns, and methodological and implementation needs rather than ranking translational maturity or implying established clinical benefit.
publication datePublication date: 2026-10-13
findingsEvidence is unevenly distributed: MS has the largest body of published work, particularly in neuroimaging, whereas studies in NMOSD, AE, and MOGAD are smaller, more heterogeneous, and often lack external validation.
limitationsTitle: Artificial intelligence in central nervous system autoimmune diseases: from clinical decision support to mechanistic discovery and translation.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.